Crispr Therapeutics shares tumble after significant earnings miss
LONDON - Hargreave Hale AIM VCT PLC has announced the allotment of 391,947 new Ordinary Shares following its recent offer to raise up to £20 million. The shares were issued at a price of 34.82 pence each, based on the net asset value as of April 11, 2025. The company expects the shares to be admitted to the premium segment of the Official List and to commence trading on the London Stock Exchange (LON:LSEG)’s main market around April 23, 2025.
The newly issued shares, which will rank equally with the existing Ordinary Shares, will bring the total number of Ordinary Shares in the company to 372,843,202. This increase in share capital also corresponds to the total voting rights, which shareholders can use as a reference for disclosure requirements under the Disclosure Guidance and Transparency Rules.
The issue of the new shares is subject to Admission, and the company has stated that definitive documents of title should be dispatched within 15 business days of allotment. Additionally, the new Ordinary Shares will be eligible for settlement through CREST upon Admission.
This share issuance is part of the company’s efforts to raise capital as outlined in its prospectus published on October 9, 2024, and the supplementary prospectus released on December 20, 2024. The offer price reflects a calculation that accounts for the costs of the offer by setting the price at a slight discount to the net asset value.
The information for this article is based on a press release statement from Hargreave Hale AIM VCT PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.